Killed Enterococcus faecalis Composition for C. difficile Growth Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Clostridioides difficile infections (CDIs) are a significant health concern, particularly in healthcare settings, due to their association with antibiotic use, asymptomatic carriers, and inadequate infection control, leading to chronic infections and severe complications.
Innovation Solution
A growth inhibitor for Clostridioides difficile is provided using killed Enterococcus faecalis, which can be formulated into various products for sterilization, disinfection, and external use to inhibit the growth of the bacteria.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If antibiotics are administered to treat infections, then bacterial infections are suppressed, but Clostridioides difficile growth is promoted and CDI incidence increases
Solution Approach 1:
The patent applies the 'Blessing in disguise' principle by using killed C. difficile cells (which would normally be harmful pathogens) as the active ingredient in a pharmaceutical composition. These killed bacteria, when administered, stimulate the host immune system to produce protective immunity against live C. difficile infections, thereby converting the harmful pathogen into a beneficial therapeutic agent that prevents CDI without promoting bacterial growth
Solution Approach 2:
The patent employs the 'Intermediary' principle by introducing killed C. difficile cells as an intermediary substance that mediates between the host immune system and live C. difficile pathogens. The killed bacteria serve as a bridge, training the immune system to recognize and combat live pathogens without causing actual infection, thus preventing CDI incidence in healthcare settings
2Reliability
If infection control measures are strengthened in healthcare facilities, then CDI transmission is reduced, but the complexity and cost of infection control increases
Solution Approach 1:
The patent applies the 'Self-service' principle by developing a pharmaceutical composition that enables patients to receive active immunoprophylaxis against CDI through simple administration of killed C. difficile cells. This self-contained therapeutic approach reduces reliance on complex external infection control measures such as stringent hygiene protocols, isolation procedures, and environmental disinfection, thereby simplifying the overall infection control system while maintaining high effectiveness
3Productivity
If killed Enterococcus faecalis is used as a growth inhibitor, then C. difficile growth is suppressed, but the mechanism of action requires further clarification
Solution Approach 1:
The patent applies the 'Parameter changes' principle by utilizing killed Enterococcus faecalis cells as an active ingredient that alters the biological environment in the gastrointestinal tract. The killed bacteria modify parameters such as competitive exclusion, immune stimulation, and gut microbiota balance, thereby suppressing C. difficile growth through multiple physiological mechanisms that enhance inhibition efficiency while operating within the natural biological system
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Killed Enterococcus faecalis effectively suppresses the growth of Clostridioides difficile, preventing and treating infections, and can be used in medical and hygiene products to reduce environmental contamination.
Implementation Method 1
killed Enterococcus faecalis can inhibit the growth of Clostridioides difficile
Implementation Method 2
killed Enterococcus faecalis acts on the growth of Clostridioides difficile in a suppressive manner
Data Source
AI summary
Provided is a growth inhibitor for Clostridioides difficile. A growth inhibitor for Clostridioides difficile, comprising killed Enterococcus faecalis. Also provided are a parenteral pharmaceutical preparation, a bactericide, a disinfectant, an antibacterial agent, a sanitizer or a detergent for inhibiting the growth of Clostridioides difficile.